|Market Size in 2022||Market Forecast in 2030||CAGR (in %)||Base Year|
|USD 11 Billion||USD 17 Billion||7%||2022|
The global apixaban market size was evaluated at $11 billion in 2022 and is slated to hit $17 billion by the end of 2030 with a CAGR of nearly 7% between 2023 and 2030.
Factor Xa is a serine protease-like trypsin that plays an important role in the cascade of blood coagulation. Apixaban mechanism works on Xa factor inhibiting which indirectly decreases thrombin-stimulated clot formation. Precisely, apixaban is an anticoagulant medicine utilized for treating and preventing blood clots & heart strokes in patients. In addition to this, Apixaban is recommended in patients with non-valvular atrial fibrillation to reduce the risk of stroke or systemic embolism.
Growing incidences of venous thromboembolism-related ailments will steer the global market trends
Rise in the occurrence of venous thromboembolism-related ailments will embellish the expansion of the apixaban market across the globe. Furthermore, the growing use of products in comparison to warfarin will further enlarge the scope of the market in the upcoming years. Apart from this, an increase in the cases of atrial fibrillation and stroke in the aging population along with surging incidences of obesity will steer the growth of the global market.
The rapid expansion of healthcare infrastructure along with enhancing healthcare awareness will aid the expansion of the market globally. A prominent surge in the demand for FDA-approved medicines will steer the expansion of the market globally. New drug launches and approvals by statutory healthcare authorities globally can prop up the scope of growth of the global market in the years ahead. For instance, in October 2022, Tiefenbacher Pharmaceuticals, a healthcare & pharmaceutical firm manufacturing generic pharmaceuticals, launched a generic kind of anticoagulant drug referred to as apixaban in Canada. The move will boost the expansion of the global market. In December 2019, the U.S. FDA approved two applications for new apixaban tablets needed for reducing the risk of systemic embolism and stroke in subjects affected by non-valvular atrial fibrillation.
Adverse drug effects on patients can put brakes on the global industry surge by 2030
Side effects of apixaban including thrombotic events and risks post premature bleeding can put brakes on the global apixaban industry expansion in the upcoming years.
Huge government investments in healthcare industry will open new growth avenues for the global market over 2023-2030
Governments are investing massively in research activities related to healthcare, thereby creating new growth opportunities for the global apixaban industry.
Low access to proper drug treatment in emerging economies can be a key challenge for the industry across the globe
Lack of availability of proper treatments in underdeveloped and developing economies can pose a huge threat to the global apixaban industry. Moreover, few of the patients are required to be treated with new modes of treatment. However, these new therapies are not available in healthcare establishments such as hospitals and ambulatory surgical centers, thereby posing a huge challenge for the global industry.
The global apixaban market is sectored into dosage form, end-user, and region.
In terms of dosage form, the global apixaban market is segregated into capsule and tablet segments. Furthermore, the capsule segment, which amassed nearly two-thirds of the global market revenue in 2022, is set to record the highest CAGR in the upcoming years. The segmental growth over the assessment timespan can be due to the massive demand for the product in capsule form by patients.
On the basis of end-users, the global apixaban industry is divided into hospitals, online pharmacies, clinics, retail pharmacies, and other segments. Furthermore, the hospitals segment, which amassed a key part of the global industry share in 2022, is slated to lead the global industry over the estimated time interval. The segmental surge over the projected timeframe can be subject to a rise in the use of apixaban in hospitals.
|Report Attributes||Report Details|
|Report Name||Apixaban Market|
|Market Size in 2022||USD 11 Billion|
|Market Forecast in 2030||USD 17 Billion|
|Growth Rate||CAGR of 7%|
|Number of Pages||204|
|Key Companies Covered||F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Eisai Co. Ltd, Sanofi S.A., Yino Pharma Limited, Mylan N.V., Bristol Myers Squibb Company, Abbott Laboratories, Hebei Changshan Biochemical Pharmaceutical Co. Ltd, Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd., Aspen Holdings, Fresenius Kabi AG, Pfizer Inc., and others.|
|Segments Covered||By Dosage Form, By End-User, and By Region|
|Regions Covered||North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)|
|Historical Year||2017 to 2021|
|Forecast Year||2023 - 2030|
|Customization Scope||Avail customized purchase options to meet your exact research needs. Request For Customization|
North America is prognosis to maintain leadership position in the global apixaban market in the forecasting timeline
North America, which contributed 57% of the global apixaban market revenue in 2022, will be a dominating region over the assessment timeline. Furthermore, the regional market expansion can be subject to a surge in the costs of medicines for venous thromboembolic disease in countries such as Canada and the U.S. Moreover, the presence of key players in the region will contribute majorly towards the regional market surge.
Asia-Pacific apixaban industry is set to record the fastest CAGR in the ensuing years owing to the presence of strong healthcare infrastructure in the countries such as India and China. In addition to this, supportive healthcare initiatives by governments in these countries will further prompt regional industry growth.
The global apixaban market profiles key players such as:
By Dosage Form
Apixaban mechanism works on Xa factor inhibiting which indirectly decreases thrombin-stimulated clot formation.
The global apixaban market growth can be owing to a rise in the occurrence of venous thromboembolism-related ailments.
According to a study, the global apixaban industry size was $11 billion in 2022 and is projected to reach $17 billion by the end of 2030.
The global apixaban market is anticipated to record a CAGR of nearly 7% from 2023 to 2030.
The Asia-Pacific apixaban industry is set to register the highest CAGR over the forecasting timeline owing to the presence of strong healthcare infrastructure in countries such as India and China. In addition to this, supportive healthcare initiatives by governments in these countries will further prompt regional industry growth.
The global apixaban market is led by players such as F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Eisai Co., Ltd, Sanofi S.A., Yino Pharma Limited, Mylan N.V., Bristol Myers Squibb Company, Abbott Laboratories, Hebei Changshan Biochemical Pharmaceutical Co. Ltd, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., Aspen Holdings, Fresenius Kabi AG, and Pfizer Inc.
The apixaban market report covers the geographical market along with a comprehensive competitive landscape analysis. It also includes cash flow analysis, profit ratio analysis, market basket analysis, market attractiveness analysis, sentiment analysis, PESTEL analysis, trend analysis, SWOT analysis, trade area analysis, demand & supply analysis, Porter’s five force analysis, and value chain analysis.